Related Experiment Video
Updated: Jun 19, 2026
05:31
Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
Published on: January 26, 2024
Early onset preeclampsia and second trimester serum markers
Geralyn M Lambert-Messerlian1, Glenn E Palomaki, Louis M Neveux
1Division of Medical Screening and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, RI, USA. gmesserl@wihri.org
Prenatal Diagnosis
|October 21, 2009
Summary
Second-trimester serum markers inhibin A, placental growth factor (PlGF), and endoglin can predict early-onset preeclampsia. Combining these markers offers individualized risk assessment for pregnant women.
Area of Science:
- Reproductive Medicine
- Maternal-Fetal Medicine
- Biomarker Discovery
Background:
- Preeclampsia is a significant complication of pregnancy with serious maternal and fetal outcomes.
- Early identification of women at risk for preeclampsia is crucial for timely intervention and improved outcomes.
- Second-trimester serum markers are being investigated for their potential in predicting preeclampsia development.
Purpose of the Study:
- To evaluate specific serum markers measured during the second trimester for their ability to identify women who will develop preeclampsia.
- To assess the predictive performance of inhibin A, soluble vascular endothelial growth factor receptor 1 (sVEGF R1), placental growth factor (PlGF), and endoglin.
Main Methods:
- Serum samples from 45 women with preeclampsia and matched controls were analyzed.
- Markers measured included inhibin A, sVEGF R1, PlGF, and endoglin.
- A multivariate model was developed using significant markers to predict preeclampsia.
Main Results:
- Inhibin A, PlGF, and endoglin showed consistent associations with preeclampsia, particularly early-onset disease.
- A predictive model incorporating these three markers identified 50% of early-onset preeclampsia cases.
- The multivariate model achieved a low false positive rate of 2%.
Conclusions:
- Second-trimester levels of inhibin A, PlGF, and endoglin can be effectively combined.
- A predictive model utilizing these markers provides individualized risk estimates for early-onset preeclampsia.
- This approach holds promise for improving early detection and management of preeclampsia.
Related Concept Videos
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.